APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Gefitinib

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Gefitinib Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173994360323 December 2025192 pages

Choose your research edition.

Industry ResearchGefitinib Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Gefitinib Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Gefitinib Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gefitinib Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Gefitinib Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Gefitinib market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Gefitinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Gefitinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Gefitinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Gefitinib is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Gefitinib include Qilu Pharmaceutical, AstraZeneca, Zuventus Healthcare, United Biotech, Sichuan Xieli Pharmaceutical, Panacea Biotec, Nobel Ilac Sanayii Ve Ticaret, Nishchay Pharmaceuticals and Natco Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Gefitinib market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Gefitinib and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Gefitinib sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Gefitinib market size, projected growth trends, production technologies, key applications, and end-use industries.

Gefitinib Segment by Company

Qilu Pharmaceutical

AstraZeneca

Zuventus Healthcare

United Biotech

Sichuan Xieli Pharmaceutical

Panacea Biotec

Nobel Ilac Sanayii Ve Ticaret

Nishchay Pharmaceuticals

Natco Pharma

Jodas Expoim

Hetero Drugs

Globela Pharma

Glenmark Pharmaceuticals

Flagship Biotech International

Ethypharm

Dr Reddy's Laboratories

Cipla

Celon Laboratories

Cadila Pharmaceuticals

Accure Labs

Gefitinib Segment by Type

10 Tables/Box

30 Tables/Box

90 Tables/Box

Gefitinib Segment by Application

Drug Center

Hospital

Clinic

Others

Gefitinib Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gefitinib market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gefitinib and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gefitinib.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Gefitinib market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Gefitinib manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Gefitinib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Gefitinib in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Gefitinib Industry Trends Table 2. Gefitinib Industry Drivers Table 3. Gefitinib Industry Opportunities and Challenges Table 4. Gefitinib Industry Restraints Table 5. Global Gefitinib Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Gefitinib Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Gefitinib Sales by Manufacturers (k pcs) & (2021-2026) Table 8. Global Gefitinib Sales Market Share by Manufacturers Table 9. Global Gefitinib Average Sales Price (US$/pcs) of Manufacturers (2021-2026) Table 10. Global Gefitinib Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Gefitinib Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Gefitinib Manufacturers, Product Type & Application Table 13. Global Gefitinib Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Gefitinib by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of 10 Tables/Box Table 17. Major Manufacturers of 30 Tables/Box Table 18. Major Manufacturers of 90 Tables/Box Table 19. Global Gefitinib Sales by Type 2021 VS 2025 VS 2032 (k pcs) Table 20. Global Gefitinib Sales by Type (2021-2026) & (k pcs) Table 21. Global Gefitinib Sales by Type (2027-2032) & (k pcs) Table 22. Global Gefitinib Sales Market Share by Type (2021-2026) Table 23. Global Gefitinib Sales Market Share by Type (2027-2032) Table 24. Global Gefitinib Revenue by Type 2021 VS 2025 VS 2032 (k pcs) Table 25. Global Gefitinib Revenue by Type (2021-2026) & (k pcs) Table 26. Global Gefitinib Revenue by Type (2027-2032) & (k pcs) Table 27. Global Gefitinib Revenue Market Share by Type (2021-2026) Table 28. Global Gefitinib Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Drug Center Table 30. Major Manufacturers of Hospital Table 31. Major Manufacturers of Clinic Table 32. Major Manufacturers of Others Table 33. Global Gefitinib Sales by Application 2021 VS 2025 VS 2032 (k pcs) Table 34. Global Gefitinib Sales by Application (2021-2026) & (k pcs) Table 35. Global Gefitinib Sales by Application (2027-2032) & (k pcs) Table 36. Global Gefitinib Sales Market Share by Application (2021-2026) Table 37. Global Gefitinib Sales Market Share by Application (2027-2032) Table 38. Global Gefitinib Revenue by Application 2021 VS 2025 VS 2032 (k pcs) Table 39. Global Gefitinib Revenue by Application (2021-2026) & (k pcs) Table 40. Global Gefitinib Revenue by Application (2027-2032) & (k pcs) Table 41. Global Gefitinib Revenue Market Share by Application (2021-2026) Table 42. Global Gefitinib Revenue Market Share by Application (2027-2032) Table 43. Global Gefitinib Sales by Region: 2021 VS 2025 VS 2032 (k pcs) Table 44. Global Gefitinib Sales by Region (2021-2026) & (k pcs) Table 45. Global Gefitinib Sales Market Share by Region (2021-2026) Table 46. Global Gefitinib Sales Forecasted by Region (2027-2032) & (k pcs) Table 47. Global Gefitinib Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Gefitinib Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k pcs) Table 49. North America Gefitinib Sales by Country (2021-2026) & (k pcs) Table 50. North America Gefitinib Sales by Country (2027-2032) & (k pcs) Table 51. Europe Gefitinib Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k pcs) Table 52. Europe Gefitinib Sales by Country (2021-2026) & (k pcs) Table 53. Europe Gefitinib Sales by Country (2027-2032) & (k pcs) Table 54. Asia Pacific Gefitinib Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k pcs) Table 55. Asia Pacific Gefitinib Sales by Country (2021-2026) & (k pcs) Table 56. Asia Pacific Gefitinib Sales by Country (2027-2032) & (k pcs) Table 57. South America, Middle East and Africa Gefitinib Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k pcs) Table 58. South America, Middle East and Africa Gefitinib Sales by Country (2021-2026) & (k pcs) Table 59. South America, Middle East and Africa Gefitinib Sales by Country (2027-2032) & (k pcs) Table 60. Global Gefitinib Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Gefitinib Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Gefitinib Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Gefitinib Revenue Market Share by Region (2021-2026) Table 64. Global Gefitinib Revenue Market Share by Region (2027-2032) Table 65. Qilu Pharmaceutical Company Information Table 66. Qilu Pharmaceutical Business Overview Table 67. Qilu Pharmaceutical Gefitinib Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Qilu Pharmaceutical Gefitinib Product Portfolio Table 69. Qilu Pharmaceutical Recent Development Table 70. AstraZeneca Company Information Table 71. AstraZeneca Business Overview Table 72. AstraZeneca Gefitinib Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. AstraZeneca Gefitinib Product Portfolio Table 74. AstraZeneca Recent Development Table 75. Zuventus Healthcare Company Information Table 76. Zuventus Healthcare Business Overview Table 77. Zuventus Healthcare Gefitinib Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Zuventus Healthcare Gefitinib Product Portfolio Table 79. Zuventus Healthcare Recent Development Table 80. United Biotech Company Information Table 81. United Biotech Business Overview Table 82. United Biotech Gefitinib Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. United Biotech Gefitinib Product Portfolio Table 84. United Biotech Recent Development Table 85. Sichuan Xieli Pharmaceutical Company Information Table 86. Sichuan Xieli Pharmaceutical Business Overview Table 87. Sichuan Xieli Pharmaceutical Gefitinib Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Sichuan Xieli Pharmaceutical Gefitinib Product Portfolio Table 89. Sichuan Xieli Pharmaceutical Recent Development Table 90. Panacea Biotec Company Information Table 91. Panacea Biotec Business Overview Table 92. Panacea Biotec Gefitinib Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Panacea Biotec Gefitinib Product Portfolio Table 94. Panacea Biotec Recent Development Table 95. Nobel Ilac Sanayii Ve Ticaret Company Information Table 96. Nobel Ilac Sanayii Ve Ticaret Business Overview Table 97. Nobel Ilac Sanayii Ve Ticaret Gefitinib Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Nobel Ilac Sanayii Ve Ticaret Gefitinib Product Portfolio Table 99. Nobel Ilac Sanayii Ve Ticaret Recent Development Table 100. Nishchay Pharmaceuticals Company Information Table 101. Nishchay Pharmaceuticals Business Overview Table 102. Nishchay Pharmaceuticals Gefitinib Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Nishchay Pharmaceuticals Gefitinib Product Portfolio Table 104. Nishchay Pharmaceuticals Recent Development Table 105. Natco Pharma Company Information Table 106. Natco Pharma Business Overview Table 107. Natco Pharma Gefitinib Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Natco Pharma Gefitinib Product Portfolio Table 109. Natco Pharma Recent Development Table 110. Jodas Expoim Company Information Table 111. Jodas Expoim Business Overview Table 112. Jodas Expoim Gefitinib Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Jodas Expoim Gefitinib Product Portfolio Table 114. Jodas Expoim Recent Development Table 115. Hetero Drugs Company Information Table 116. Hetero Drugs Business Overview Table 117. Hetero Drugs Gefitinib Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Hetero Drugs Gefitinib Product Portfolio Table 119. Hetero Drugs Recent Development Table 120. Globela Pharma Company Information Table 121. Globela Pharma Business Overview Table 122. Globela Pharma Gefitinib Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Globela Pharma Gefitinib Product Portfolio Table 124. Globela Pharma Recent Development Table 125. Glenmark Pharmaceuticals Company Information Table 126. Glenmark Pharmaceuticals Business Overview Table 127. Glenmark Pharmaceuticals Gefitinib Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Glenmark Pharmaceuticals Gefitinib Product Portfolio Table 129. Glenmark Pharmaceuticals Recent Development Table 130. Flagship Biotech International Company Information Table 131. Flagship Biotech International Business Overview Table 132. Flagship Biotech International Gefitinib Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Flagship Biotech International Gefitinib Product Portfolio Table 134. Flagship Biotech International Recent Development Table 135. Ethypharm Company Information Table 136. Ethypharm Business Overview Table 137. Ethypharm Gefitinib Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Ethypharm Gefitinib Product Portfolio Table 139. Ethypharm Recent Development Table 140. Dr Reddy's Laboratories Company Information Table 141. Dr Reddy's Laboratories Business Overview Table 142. Dr Reddy's Laboratories Gefitinib Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 143. Dr Reddy's Laboratories Gefitinib Product Portfolio Table 144. Dr Reddy's Laboratories Recent Development Table 145. Cipla Company Information Table 146. Cipla Business Overview Table 147. Cipla Gefitinib Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 148. Cipla Gefitinib Product Portfolio Table 149. Cipla Recent Development Table 150. Celon Laboratories Company Information Table 151. Celon Laboratories Business Overview Table 152. Celon Laboratories Gefitinib Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 153. Celon Laboratories Gefitinib Product Portfolio Table 154. Celon Laboratories Recent Development Table 155. Cadila Pharmaceuticals Company Information Table 156. Cadila Pharmaceuticals Business Overview Table 157. Cadila Pharmaceuticals Gefitinib Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 158. Cadila Pharmaceuticals Gefitinib Product Portfolio Table 159. Cadila Pharmaceuticals Recent Development Table 160. Accure Labs Company Information Table 161. Accure Labs Business Overview Table 162. Accure Labs Gefitinib Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 163. Accure Labs Gefitinib Product Portfolio Table 164. Accure Labs Recent Development Table 165. Key Raw Materials Table 166. Raw Materials Key Suppliers Table 167. Gefitinib Distributors List Table 168. Gefitinib Customers List Table 169. Research Programs/Design for This Report Table 170. Authors List of This Report Table 171. Secondary Sources Table 172. Primary Sources List of Figures Figure 1. Gefitinib Product Image Figure 2. Global Gefitinib Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gefitinib Market Size (2021-2032) & (US$ Million) Figure 4. Global Gefitinib Sales (2021-2032) & (k pcs) Figure 5. Global Gefitinib Average Price (US$/pcs) & (2021-2032) Figure 6. Global Top 5 and 10 Gefitinib Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. 10 Tables/Box Image Figure 9. 30 Tables/Box Image Figure 10. 90 Tables/Box Image Figure 11. Global Gefitinib Sales by Type (2021 VS 2025 VS 2032) & (k pcs) Figure 12. Global Gefitinib Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Gefitinib Sales Market Share by Type (2021-2032) Figure 14. Global Gefitinib Revenue by Type (2021 VS 2025 VS 2032) & (k pcs) Figure 15. Global Gefitinib Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Gefitinib Revenue Market Share by Type (2021-2032) Figure 17. Drug Center Image Figure 18. Hospital Image Figure 19. Clinic Image Figure 20. Others Image Figure 21. Global Gefitinib Sales by Application (2021 VS 2025 VS 2032) & (k pcs) Figure 22. Global Gefitinib Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Gefitinib Sales Market Share by Application (2021-2032) Figure 24. Global Gefitinib Revenue by Application (2021 VS 2025 VS 2032) & (k pcs) Figure 25. Global Gefitinib Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Gefitinib Revenue Market Share by Application (2021-2032) Figure 27. North America Gefitinib Sales and Growth Rate (2021-2032) & (k pcs) Figure 28. North America Gefitinib Sales Market Share by Country (2021-2032) Figure 29. U.S. Gefitinib Sales and Growth Rate (2021-2032) & (k pcs) Figure 30. Canada Gefitinib Sales and Growth Rate (2021-2032) & (k pcs) Figure 31. Mexico Gefitinib Sales and Growth Rate (2021-2032) & (k pcs) Figure 32. Europe Gefitinib Sales and Growth Rate (2021-2032) & (k pcs) Figure 33. Europe Gefitinib Sales Market Share by Country (2021-2032) Figure 34. Germany Gefitinib Sales and Growth Rate (2021-2032) & (k pcs) Figure 35. France Gefitinib Sales and Growth Rate (2021-2032) & (k pcs) Figure 36. U.K. Gefitinib Sales and Growth Rate (2021-2032) & (k pcs) Figure 37. Italy Gefitinib Sales and Growth Rate (2021-2032) & (k pcs) Figure 38. Netherlands Gefitinib Sales and Growth Rate (2021-2032) & (k pcs) Figure 39. Asia Pacific Gefitinib Sales and Growth Rate (2021-2032) & (k pcs) Figure 40. Asia Pacific Gefitinib Sales Market Share by Country (2021-2032) Figure 41. China Gefitinib Sales and Growth Rate (2021-2032) & (k pcs) Figure 42. Japan Gefitinib Sales and Growth Rate (2021-2032) & (k pcs) Figure 43. South Korea Gefitinib Sales and Growth Rate (2021-2032) & (k pcs) Figure 44. Southeast Asia Gefitinib Sales and Growth Rate (2021-2032) & (k pcs) Figure 45. India Gefitinib Sales and Growth Rate (2021-2032) & (k pcs) Figure 46. Australia Gefitinib Sales and Growth Rate (2021-2032) & (k pcs) Figure 47. South America, Middle East and Africa Gefitinib Sales and Growth Rate (2021-2032) & (k pcs) Figure 48. South America, Middle East and Africa Gefitinib Sales Market Share by Country (2021-2032) Figure 49. Brazil Gefitinib Sales and Growth Rate (2021-2032) & (k pcs) Figure 50. South Africa Gefitinib Sales and Growth Rate (2021-2032) & (k pcs) Figure 51. Saudi Arabia Gefitinib Sales and Growth Rate (2021-2032) & (k pcs) Figure 52. Turkey Gefitinib Sales and Growth Rate (2021-2032) & (k pcs) Figure 53. Argentina Gefitinib Sales and Growth Rate (2021-2032) & (k pcs) Figure 54. UAE Gefitinib Sales and Growth Rate (2021-2032) & (k pcs) Figure 55. Egypt Gefitinib Sales and Growth Rate (2021-2032) & (k pcs) Figure 56. Chile Gefitinib Sales and Growth Rate (2021-2032) & (k pcs) Figure 57. Global Gefitinib Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Gefitinib Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Gefitinib Revenue (2021-2032) & (US$ Million) Figure 60. North America Gefitinib Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Gefitinib Revenue (2021-2032) & (US$ Million) Figure 62. Europe Gefitinib Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Gefitinib Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Gefitinib Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Gefitinib Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Gefitinib Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Gefitinib Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Gefitinib Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • 10 Tables/Box
  • 30 Tables/Box
  • 90 Tables/Box
Applications
  • Drug Center
  • Hospital
  • Clinic
  • Others
Companies covered
  • Qilu Pharmaceutical
  • AstraZeneca
  • Zuventus Healthcare
  • United Biotech
  • Sichuan Xieli Pharmaceutical
  • Panacea Biotec
  • Nobel Ilac Sanayii Ve Ticaret
  • Nishchay Pharmaceuticals
  • Natco Pharma
  • Jodas Expoim
  • Hetero Drugs
  • Globela Pharma
  • Glenmark Pharmaceuticals
  • Flagship Biotech International
  • Ethypharm
  • Dr Reddy's Laboratories
  • Cipla
  • Celon Laboratories
  • Cadila Pharmaceuticals
  • Accure Labs

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Gefitinib Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Gefitinib Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Gefitinib Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Gefitinib Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Gefitinib Market Dynamics
  1. 2.1 Gefitinib Industry Trends
  2. 2.2 Gefitinib Industry Drivers
  3. 2.3 Gefitinib Industry Opportunities and Challenges
  4. 2.4 Gefitinib Industry Restraints
3 Gefitinib Market by Manufacturers
  1. 3.1 Global Gefitinib Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Gefitinib Sales by Manufacturers (2021-2026)
  3. 3.3 Global Gefitinib Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Gefitinib Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Gefitinib Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Gefitinib Manufacturers, Product Type & Application
  7. 3.7 Global Gefitinib Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Gefitinib Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Gefitinib Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Gefitinib Tier 1, Tier 2, and Tier 3
4 Gefitinib Market by Type
  1. 4.1 Gefitinib Type Introduction
  2. 4.1.1 10 Tables/Box
  3. 4.1.2 30 Tables/Box
  4. 4.1.3 90 Tables/Box
  5. 4.2 Global Gefitinib Sales by Type
  6. 4.2.1 Global Gefitinib Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Gefitinib Sales by Type (2021-2032)
  8. 4.2.3 Global Gefitinib Sales Market Share by Type (2021-2032)
  9. 4.3 Global Gefitinib Revenue by Type
  10. 4.3.1 Global Gefitinib Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Gefitinib Revenue by Type (2021-2032)
  12. 4.3.3 Global Gefitinib Revenue Market Share by Type (2021-2032)
5 Gefitinib Market by Application
  1. 5.1 Gefitinib Application Introduction
  2. 5.1.1 Drug Center
  3. 5.1.2 Hospital
  4. 5.1.3 Clinic
  5. 5.1.4 Others
  6. 5.2 Global Gefitinib Sales by Application
  7. 5.2.1 Global Gefitinib Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Gefitinib Sales by Application (2021-2032)
  9. 5.2.3 Global Gefitinib Sales Market Share by Application (2021-2032)
  10. 5.3 Global Gefitinib Revenue by Application
  11. 5.3.1 Global Gefitinib Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Gefitinib Revenue by Application (2021-2032)
  13. 5.3.3 Global Gefitinib Revenue Market Share by Application (2021-2032)
6 Global Gefitinib Sales by Region
  1. 6.1 Global Gefitinib Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Gefitinib Sales by Region (2021-2032)
  3. 6.2.1 Global Gefitinib Sales by Region (2021-2026)
  4. 6.2.2 Global Gefitinib Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Gefitinib Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Gefitinib Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Gefitinib Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Gefitinib Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Gefitinib Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Gefitinib Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Gefitinib Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Gefitinib Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Gefitinib Revenue by Region
  1. 7.1 Global Gefitinib Revenue by Region
  2. 7.1.1 Global Gefitinib Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Gefitinib Revenue by Region (2021-2026)
  4. 7.1.3 Global Gefitinib Revenue by Region (2027-2032)
  5. 7.1.4 Global Gefitinib Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Gefitinib Revenue (2021-2032)
  8. 7.2.2 North America Gefitinib Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Gefitinib Revenue (2021-2032)
  11. 7.3.2 Europe Gefitinib Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Gefitinib Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Gefitinib Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Gefitinib Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Gefitinib Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Qilu Pharmaceutical
  2. 8.1.1 Qilu Pharmaceutical Company Information
  3. 8.1.2 Qilu Pharmaceutical Business Overview
  4. 8.1.3 Qilu Pharmaceutical Gefitinib Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Qilu Pharmaceutical Gefitinib Product Portfolio
  6. 8.1.5 Qilu Pharmaceutical Recent Developments
  7. 8.2 AstraZeneca
  8. 8.2.1 AstraZeneca Company Information
  9. 8.2.2 AstraZeneca Business Overview
  10. 8.2.3 AstraZeneca Gefitinib Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 AstraZeneca Gefitinib Product Portfolio
  12. 8.2.5 AstraZeneca Recent Developments
  13. 8.3 Zuventus Healthcare
  14. 8.3.1 Zuventus Healthcare Company Information
  15. 8.3.2 Zuventus Healthcare Business Overview
  16. 8.3.3 Zuventus Healthcare Gefitinib Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Zuventus Healthcare Gefitinib Product Portfolio
  18. 8.3.5 Zuventus Healthcare Recent Developments
  19. 8.4 United Biotech
  20. 8.4.1 United Biotech Company Information
  21. 8.4.2 United Biotech Business Overview
  22. 8.4.3 United Biotech Gefitinib Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 United Biotech Gefitinib Product Portfolio
  24. 8.4.5 United Biotech Recent Developments
  25. 8.5 Sichuan Xieli Pharmaceutical
  26. 8.5.1 Sichuan Xieli Pharmaceutical Company Information
  27. 8.5.2 Sichuan Xieli Pharmaceutical Business Overview
  28. 8.5.3 Sichuan Xieli Pharmaceutical Gefitinib Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sichuan Xieli Pharmaceutical Gefitinib Product Portfolio
  30. 8.5.5 Sichuan Xieli Pharmaceutical Recent Developments
  31. 8.6 Panacea Biotec
  32. 8.6.1 Panacea Biotec Company Information
  33. 8.6.2 Panacea Biotec Business Overview
  34. 8.6.3 Panacea Biotec Gefitinib Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Panacea Biotec Gefitinib Product Portfolio
  36. 8.6.5 Panacea Biotec Recent Developments
  37. 8.7 Nobel Ilac Sanayii Ve Ticaret
  38. 8.7.1 Nobel Ilac Sanayii Ve Ticaret Company Information
  39. 8.7.2 Nobel Ilac Sanayii Ve Ticaret Business Overview
  40. 8.7.3 Nobel Ilac Sanayii Ve Ticaret Gefitinib Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Nobel Ilac Sanayii Ve Ticaret Gefitinib Product Portfolio
  42. 8.7.5 Nobel Ilac Sanayii Ve Ticaret Recent Developments
  43. 8.8 Nishchay Pharmaceuticals
  44. 8.8.1 Nishchay Pharmaceuticals Company Information
  45. 8.8.2 Nishchay Pharmaceuticals Business Overview
  46. 8.8.3 Nishchay Pharmaceuticals Gefitinib Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Nishchay Pharmaceuticals Gefitinib Product Portfolio
  48. 8.8.5 Nishchay Pharmaceuticals Recent Developments
  49. 8.9 Natco Pharma
  50. 8.9.1 Natco Pharma Company Information
  51. 8.9.2 Natco Pharma Business Overview
  52. 8.9.3 Natco Pharma Gefitinib Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Natco Pharma Gefitinib Product Portfolio
  54. 8.9.5 Natco Pharma Recent Developments
  55. 8.10 Jodas Expoim
  56. 8.10.1 Jodas Expoim Company Information
  57. 8.10.2 Jodas Expoim Business Overview
  58. 8.10.3 Jodas Expoim Gefitinib Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Jodas Expoim Gefitinib Product Portfolio
  60. 8.10.5 Jodas Expoim Recent Developments
  61. 8.11 Hetero Drugs
  62. 8.11.1 Hetero Drugs Company Information
  63. 8.11.2 Hetero Drugs Business Overview
  64. 8.11.3 Hetero Drugs Gefitinib Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Hetero Drugs Gefitinib Product Portfolio
  66. 8.11.5 Hetero Drugs Recent Developments
  67. 8.12 Globela Pharma
  68. 8.12.1 Globela Pharma Company Information
  69. 8.12.2 Globela Pharma Business Overview
  70. 8.12.3 Globela Pharma Gefitinib Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Globela Pharma Gefitinib Product Portfolio
  72. 8.12.5 Globela Pharma Recent Developments
  73. 8.13 Glenmark Pharmaceuticals
  74. 8.13.1 Glenmark Pharmaceuticals Company Information
  75. 8.13.2 Glenmark Pharmaceuticals Business Overview
  76. 8.13.3 Glenmark Pharmaceuticals Gefitinib Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Glenmark Pharmaceuticals Gefitinib Product Portfolio
  78. 8.13.5 Glenmark Pharmaceuticals Recent Developments
  79. 8.14 Flagship Biotech International
  80. 8.14.1 Flagship Biotech International Company Information
  81. 8.14.2 Flagship Biotech International Business Overview
  82. 8.14.3 Flagship Biotech International Gefitinib Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Flagship Biotech International Gefitinib Product Portfolio
  84. 8.14.5 Flagship Biotech International Recent Developments
  85. 8.15 Ethypharm
  86. 8.15.1 Ethypharm Company Information
  87. 8.15.2 Ethypharm Business Overview
  88. 8.15.3 Ethypharm Gefitinib Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Ethypharm Gefitinib Product Portfolio
  90. 8.15.5 Ethypharm Recent Developments
  91. 8.16 Dr Reddy's Laboratories
  92. 8.16.1 Dr Reddy's Laboratories Company Information
  93. 8.16.2 Dr Reddy's Laboratories Business Overview
  94. 8.16.3 Dr Reddy's Laboratories Gefitinib Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Dr Reddy's Laboratories Gefitinib Product Portfolio
  96. 8.16.5 Dr Reddy's Laboratories Recent Developments
  97. 8.17 Cipla
  98. 8.17.1 Cipla Company Information
  99. 8.17.2 Cipla Business Overview
  100. 8.17.3 Cipla Gefitinib Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Cipla Gefitinib Product Portfolio
  102. 8.17.5 Cipla Recent Developments
  103. 8.18 Celon Laboratories
  104. 8.18.1 Celon Laboratories Company Information
  105. 8.18.2 Celon Laboratories Business Overview
  106. 8.18.3 Celon Laboratories Gefitinib Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Celon Laboratories Gefitinib Product Portfolio
  108. 8.18.5 Celon Laboratories Recent Developments
  109. 8.19 Cadila Pharmaceuticals
  110. 8.19.1 Cadila Pharmaceuticals Company Information
  111. 8.19.2 Cadila Pharmaceuticals Business Overview
  112. 8.19.3 Cadila Pharmaceuticals Gefitinib Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Cadila Pharmaceuticals Gefitinib Product Portfolio
  114. 8.19.5 Cadila Pharmaceuticals Recent Developments
  115. 8.20 Accure Labs
  116. 8.20.1 Accure Labs Company Information
  117. 8.20.2 Accure Labs Business Overview
  118. 8.20.3 Accure Labs Gefitinib Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Accure Labs Gefitinib Product Portfolio
  120. 8.20.5 Accure Labs Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Gefitinib Value Chain Analysis
  2. 9.1.1 Gefitinib Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Gefitinib Production Mode & Process
  6. 9.2 Gefitinib Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Gefitinib Distributors
  9. 9.2.3 Gefitinib Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst